Sarcosine – Kodiac biolabs

Plain-language summaryIntrigue 60 / 100

Sarcosine is an N-methylated version of the amino acid glycine, made naturally in your body. It blocks the GlyT1 transporter that normally clears glycine from the synapse, so glycine builds up near NMDA receptors and boosts their function (glycine is the other co-agonist alongside D-serine). This is essentially a back-door way to enhance NMDA signaling without giving D-serine directly. Phase 2 trials added it to standard antipsychotics in schizophrenia and to antidepressants in depression, with small to moderate effects on negative symptoms and mood. Bitopertin, a more potent selective GlyT1 inhibitor, ran the same play but failed phase 3, which tempered enthusiasm for the whole approach. Reference compound for glycine-transporter pharmacology. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

49/100

Canonical GlyT1 research probe with real phase 2 data, but bitopertin’s failure shadows the class

Look, sarcosine has a legitimately interesting story. N-methylglycine acts as a competitive substrate at GlyT1, blocking glycine reuptake and raising extracellular glycine near NMDA receptors. The glycine co-agonist site is a real pharmacological target, distinct from the glutamate site and from direct agonism, and for investigators studying NMDA hypofunction biology this is the relevant mechanism. Sarcosine complements D-serine administration as a different route to the same destination: more glycinergic tone at NMDA receptors without direct receptor activation.

The clinical story is mixed but not empty. Phase 2 adjunct trials in schizophrenia, primarily alongside risperidone and olanzapine, produced small-to-moderate improvements in negative symptoms. That’s worth noting because negative symptoms are the piece of schizophrenia that antipsychotics basically dont touch. A separate phase 2 signal in MDD exists too, though thinner. Effect sizes are real and statistically meaningful in several trials; multi-lab replication exists. No phase 3 has been run for sarcosine itself, which limits how far the evidence can carry you.

Here’s what weighs heavily against it: bitopertin. RG1678 was the field’s best attempt to turn potent, selective GlyT1 inhibition into an approved drug, and it failed three phase 3 trials in schizophrenia negative symptoms. That failure doesn’t indict sarcosine’s bench utility, but it does cast a long shadow over GlyT1 as a therapeutic pivot. Either the NMDA hypofunction theory doesn’t translate the way the preclinical mechanism predicts, or the effect size ceiling is too low to clear phase 3, or both. Investigators building a program around this axis need to reckon with that history before committing resources.

What sarcosine does well is its probe role. It remains the canonical tool for GlyT1 substrate inhibition studies, indexed across decades of mechanistic literature. If you’re characterizing NMDA co-agonist site pharmacology, measuring glycine spillover kinetics, or interrogating GlyT1 transporter behavior in a CNS model, sarcosine is accessible, well-characterized, and genuinely useful. Thats real bench value, even if its not frontier value.

We think the right framing is: sarcosine is a solid niche probe for a defined research program with a modest but real clinical signal that’s already been tested hard by drug development. The mechanism isn’t new, the bitopertin data tells you something about the ceiling, and the novelty story stopped compounding years ago. Score reflects that. Useful for investigators already operating in NMDA co-agonist or GlyT1 biology; not a reason to start a new program from scratch in 2026.

Novelty: 38
Mechanism promise: 55
In-category differentiation: 50
Evidence quality: 50
Translational signal: 45
Research bench value: 65

Rationale Sarcosine earns its score on genuine bench probe utility and multi-lab phase 2 clinical data across schizophrenia and MDD, but the mechanism is established not novel, and bitopertin’s consecutive phase 3 failures between 2013-2016 put a hard ceiling on enthusiasm for the GlyT1 therapeutic angle. No amino acid cap applies: GlyT1 transporter pharmacology distinguishes sarcosine clearly from plain glycine, analogous to how sulbutiamine differs from thiamine.

Glycine reuptake inhibitor (GlyT1)

N-methylglycine; an endogenous methylglycine that inhibits glycine reuptake at GlyT1, elevating synaptic glycine.

Abstract

Sarcosine (N-methylglycine; CAS 107-97-1; molecular formula C3H7NO2; molecular weight 89.09) is an endogenous N-methylated derivative of glycine and a competitive substrate of the glycine transporter type 1 (GlyT1). Pharmacologically, sarcosine inhibits glycine reuptake at GlyT1, elevating extracellular glycine concentrations near NMDA receptors and consequently enhancing NMDA receptor function via the glycine co-agonist site. The mechanism complements direct D-serine administration. Phase 2 trials in schizophrenia (as adjunct to risperidone or olanzapine) and major depressive disorder have shown small to moderate effects on negative symptoms and depressive symptoms. Plasma half-life is approximately 7 hours; the compound is well tolerated. The selective GlyT1 inhibitor bitopertin (RG1678) was developed as a more potent alternative but failed phase 3 trials. Used as the canonical GlyT1 substrate inhibitor in NMDA receptor research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-375Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.